INTRODUCTION
The treatment outcome of pulmonary arterial hypertension (PAH), a severe form of pulmonary vascular disease, has been disappointing, and thus patient survival rate continues to bẽ 80 and~50% after 1 and 5 yr of diagnosis, respectively (9) .
A better understanding of PAH pathogenesis over the past two decades has spurred the development of more effective therapies for PAH, and thus various types of drugs are commercially available and clinically used for the treatment of this incurable disease (27) . Though relatively newer molecules function by interrupting an array of signaling pathways, all existing drugs are predominantly vasodilators. They have no direct effect on pulmonary arterial remodeling, which leads to right ventricular hypertrophy (RVH), the major cause of death from PAH (49) . Dual-or triple-vasodilator combinations, given either as a sequential or up-front regimen, although improving patient morbidity and survival rate, have been of limited help in reversing progressive deterioration of pulmonary arterial remodeling (11, 30, 32) . Besides orally administered vasodilators, two approved PAH medications, treprostinil and iloprost, are currently available as inhalable solutions, which are currently used to treat only adult patients with PAH (63, 64) . Inhaled iloprost or treprostinil is used to prevent acute exacerbation of PAH, but inhaled forms of these drugs are not used as replacements for their intravenous or oral counterparts. Furthermore, multiple dosing a day (the dosing frequencies of treprostinil and iloprost are 4 and 6 -9 times a day, respectively), cumbersome inhalation devices, and side effects such as bronchoconstriction, cough, and increased airway reactivity seriously restrict their clinical applications (63, 64) . In addition, because of the safety concerns, inhaled anti-PAH medications are not recommended for pediatric patients who are 8 yr old or younger, an important cohort of patients with PAH (24, 56) .
To address the limitations of multiple dosing for inhaled anti-PAH drugs, we previously demonstrated that dosing interval can be extended and thus the dosing frequency for anti-PAH medications can be reduced by administering the drugs as inhalable sustained-release particulate formulations (16, 18, 39, 40) . We have shown that inhalable drug-laden particles, given either in the form of biodegradable polymeric particles or liposomes, can elicit pulmonary-specific effects of anti-PAH drugs at a reduced dosing frequency (15) (16) (17) 40) . The inhaled formulations of various anti-PAH drugs including prostaglandin E 1 , fasudil, long-acting nitric oxide donors, and superoxide dismutase, when formulated as polymeric or lipidic particles, can minimize drops in systemic arterial pressure by restricting the drugs' vasodilatory effects within the pulmonary vasculature. In a recent study, we showed that by formulating it as inhalable particles, rosiglitazone, a peroxisome proliferator-activated receptor-␥ agonist that is reported to inhibit pul-monary arterial remodeling and arrest PAH progression (14, 28, 33, 41, 54) , can be repurposed for the treatment of PAH (46) . In a separate study, we demonstrated that inhaled poly-(lactic-co-glycolic acid) (PLGA) particles of sildenafil, an orally active phosphodiesterase type 5 inhibitor that is frequently used as monotherapy or in combination therapy for PAH (13) , improve pulmonary hemodynamics in PAH rats when given at a reduced dose and longer dosing intervals (48) .
As a continuation of the above two studies (46, 48) , wherein we assessed the feasibility of inhaled particulate formulations of rosiglitazone and sildenafil for the treatment of PAH, here we tested the hypothesis that a combination of sildenafil and rosiglitazone, when given as prolonged-release formulations via the pulmonary route, improves pulmonary hemodynamics, RVH, and pulmonary arterial remodeling. As such, we first prepared PLGA particles of sildenafil and rosiglitazone and assessed them for their suitability for administration via the pulmonary route. After intratracheal (IT) administration of 1) plain drugs, 2) PLGA particles of either sildenafil or rosiglitazone, and 3) combination of PLGA particles of sildenafil plus rosiglitazone to PAH rats for 3 wk, we measured pulmonary hemodynamics and assessed the effect of the formulations on RVH and pulmonary arterial remodeling upon morphometric analysis.
MATERIALS AND METHODS
Materials. PLGA polymers (lactic-to-glycolate ratios of 50:50 and 75:25; inherent viscosity 0.55-0.75 dl/g) were purchased from Lactel Absorbable Polymers (Birmingham, AL). Sildenafil citrate and rosiglitazone maleate were from Biotang (Lexington, MA) and Cayman Chemical (Ann Arbor, MI), respectively. Male Sprague-Dawley rats (250 -350 g) were obtained from Charles River Laboratories (Wilmington, MA). All other chemicals were of HPLC grade and were purchased from Sigma-Aldrich (St. Louis, MO).
Preparation and characterization of PLGA particles of sildenafil and rosiglitazone. Sildenafil-and rosiglitazone-loaded microparticles were prepared according to our previously established water-in-oilin-water (W 1/O/W2) double emulsion-solvent evaporation method (46, 48) . In short, 0.5 ml of an internal aqueous phase (W1) containing rosiglitazone maleate (20 mg/ml) or sildenafil citrate (20 mg/ml) in a mixture of methanol and double-deionized water (20:80) plus 0.5% polyethyleneimine (PEI) in water was first emulsified in a PLGA polymer solution in dichloromethane (organic phase) using a Branson Sonifier 450 (Branson Ultrasonics, Danbury, CT). The organic phase for preparing sildenafil and rosiglitazone particles had 250 mg of PLGA 75:25 polymer in 5 ml of dichloromethane and 100 mg of PLGA 50:50 polymer in 5 ml of dichloromethane, respectively. A double emulsion was prepared by homogenizing the primary (W 1/O) emulsion with 0.5% wt/vol polyvinyl alcohol solution (electroactive polymer, W 2). The double emulsion was then stirred for 8 h at room temperature for evaporation of the organic phase and hardening of the particles. The polymeric particles were then washed three times with water and lyophilized for 48 h to obtain free-flowing powdered formulations.
Both sildenafil-and rosiglitazone-loaded particles were characterized for their size, zeta potential, and encapsulation efficiency. The volume-based mean diameter and particle size distribution of the formulations were determined in a Malvern Mastersizer 2000 (Malvern Instruments, Malvern, UK) particle size analyzer. Freezedried particles (~15 mg) were dispersed in deionized water using a Hydro 2000MU sample dispersion unit and pumped into the particle size analyzer. The zeta potential was measured using a Nano ZS90 Zetasizer (Malvern Instruments) after dispersing equal amounts of particles in 1ϫ PBS buffer. The entrapment efficiencies of the formulations were determined directly by dissolving~5 mg of freeze-dried particles in a 1:1:1 mixture of methanol-dimethyl sulfoxidedichloromethane. The UV absorbance was measured at 311 and 293 nm for sildenafil and rosiglitazone, respectively, using a spectrophotometer (Hewlett Packard, Palo Alto, CA). The concentrations in the dissolved particles were obtained from a calibration curve of absorbance versus concentration of sildenafil citrate or rosiglitazone maleate. The entrapment efficiency was calculated using the following equation: entrapment efficiency (%) ϭ (amount of drug in particles/ amount of drug originally added) ϫ 100.
Effect of the formulations on pulmonary hemodynamics, cardiac function, and arterial remodeling. The long-term efficacy studies were conducted in Sugen-hypoxia-induced PAH rats as described previously (42, 55, 66; Fig. 1 ). For development of PAH, adult male Sprague-Dawley rats (200 -225 g; Charles River) were given a single subcutaneous injection of Sugen 5416 (20 mg/kg; Bio-Techne, Minneapolis, MN) (composition: 20 mg/kg Sugen 5416 and 0.5% carboxymethyl cellulose, 0.9% NaCl, 0.4% Tween 20, and 0.9% benzyl alcohol wt/vol in water), and then Sugen 5416-treated rats were kept in a hypoxia chamber (BioSpherix, Lacona, NY) at 10% oxygen for 3 wk. Animals had free access to food and water. On the 22nd day, rats were removed from the hypoxic chamber and housed in normoxia for an additional 3 wk. During these 21 days, when rats were housed in normoxia, PAH rats were divided into eight groups to receive 1) IT 100 l saline, once a day; 2) oral plain sildenafil, once a day; 3) oral plain rosiglitazone, once a day; 4) IT plain sildenafil, once a day; 5) IT plain rosiglitazone, once a day; 6) oral plain sildenafil and plain rosiglitazone combination, once a day; 7) IT plain sildenafil and plain rosiglitazone combination, once a day; or 8) IT sildenafil particle and rosiglitazone particle combination, every 48 h (Fig. 1 ). The doses of sildenafil and rosiglitazone were 0.5 and 0.3 mg/kg, respectively. One group of healthy rats was used as the sham group. IT administration was performed using a Penn Century MicroSprayer (Penn Century, Wyndmoor, PA) upon illuminating the trachea using a rat laryngoscope, as reported previously (48) .
Measurement for pulmonary hemodynamics and cardiac functional parameters. To measure mean pulmonary arterial pressure (mPAP) and mean systemic arterial pressure (mSAP), PAH rats were anesthetized by intramuscular administration of ketamine and xylazine, and the ventral neck area of the rats was shaved and then cleaned using ethyl alcohol. To measure mPAP, a polyvinyl catheter (PV-1, 0.28-mm internal diameter, Tygon) was inserted into the right jugular vein to reach the pulmonary artery via the right ventricle. For mSAP, a Millar pressure-volume catheter (SPR-868; Millar, Houston, TX) was inserted into the left ventricle through the right carotid artery. The data were recorded in a PowerLab 16/30 system (ADInstruments, Colorado Springs, CO) equipped with Millar Pressure-Volume System (MPVS) Ultra (Millar) using LabChart Pro 7.0 software (ADInstruments). mPAP was measured using MEMSCAP SP844 physiological pressure transducers (MEMSCAP, Skoppum, Norway) and bridge amplifier (19) , whereas mSAP was measured using MPVS Ultra. The signals were continuously recorded for 30 min (Fig. 1) . A cardiac pressure-volume relationship (P-V loop) in the left ventricle was assessed to obtain hemodynamic parameters using a pressure-volume analysis program of the Lab-Chart Pro 7.0 software. mSAP and cardiac output were measured by analyzing the P-V loops. Cardiac index (CI), the weightnormalized cardiac output, was also obtained by dividing the cardiac output by the body weight of the animal (1, 67) . The total pulmonary vascular resistance (TPVR) was calculated by dividing the mPAP by the respective cardiac output (34, 50, 67, 69) . After each hemodynamic study, the rats were euthanized, and the lungs and hearts were collected for morphometric analyses and calculation of RV weight-to-LV plus septum weight ratio (RV/LVϩS), respectively. Animal studies were performed by following the NIH's Guideline for the Care and Use of Laboratory Animals under an approved protocol (AM-10012) from Texas Tech University Health Sciences Center Animal Care and Use Committee.
Preparation of lung samples for morphometric studies. After measuring the pulmonary hemodynamics, lung tissues were collected and fixed with 10% formalin solution; the chest was opened, and heart and lungs were exposed. The left lung was inflated and fixed with 10% formalin under 30-cmH 2O pressure (7) . The heart and lungs were then removed en bloc from the body and stored in paraformaldehyde for a day. To measure RVH, the heart was removed from the block. Afterward, the left lung was transferred to 70% ethanol in water before embedding in paraffin blocks to be used for morphometric analyses.
Assessment of RVH and immunostaining for morphometric analysis. RVH was measured from RV/LVϩS as previously described (47) . Lung sections (5 m) from formalin-fixed and paraffin-embedded left lungs were deparaffinized with CitriSolv (Thermo Fisher Scientific, Pittsburgh, PA) and subsequently rehydrated with a series of gradient ethanol in water. Sections were boiled in antigen-unmasking solution, blocked using 10% horse serum (Vector, Burlingame, CA), incubated overnight first with a mouse monoclonal ␣-smooth muscle actin (␣-SMA) antibody, clone 1A4 (Sigma-Aldrich), and then with peroxidase-conjugated anti-mouse/anti-rabbit secondary anti-body (R.T.U. Vectastain Universal; Vector), and finally stained with peroxidase-sensitive ImmPACT diaminobenzidine substrate (Vector). Similarly, von Willebrand factor (vWF) was stained with rabbit polyclonal anti-vWF antibody (Sigma-Aldrich) and peroxidase-sensitive ImmPACT VIP substrate (Vector; 65). Nuclei were counterstained with methyl green (Vector), and slides were viewed at ϫ200 using an Aperio ScanScope system (Leica Biosystems, Buffalo Grove, IL). A positive pixel count algorithm was created using Aperio ImageScope software (Leica Biosystems) to determine the degree of muscularization and measure the medial wall thickness (MWT).
Quantitation of the degree of muscularization and arterial MWT. For the quantitation of the muscularized vessels, we counted the number of blood vessels that were Ͻ50 m in diameter and had a positive ␣-SMA stain in 10 fields of view (ϫ10 magnification). Muscularized pulmonary arteries and arterioles that occupied Ͼ50% of the diameter of the lumen and intima of the vessels were considered as muscularized arteries. For MWT, four measurements of the perpendicular lumen radius and medial wall were taken for small muscularized arteries (Ͻ50 m). MWT was expressed as the average MWT divided by the average vessel radius. The ␣-SMA staining was evaluated by an investigator blinded to the treatment groups.
Collagen analysis. The slides containing slices of the lungs were deparaffinized and stained using a Masson's trichrome staining kit (HT15-1KT; Sigma-Aldrich) to visualize and quantify collagen deposition around the pulmonary arteries. Briefly, lung sections (100 m) were deparaffinized with CitriSolv (Thermo Fisher Scientific) and rehydrated in graded ethanol followed by deionized water. Sections were then treated with preheated Bouin solution for 15 min followed by sequential treatment with Weigert's hematoxylin, Biebrich scarletacid fuschin, phosphotungstic/phosphomolybdic acid, aniline blue, and 1% acetic acid solutions. Finally, stained sections were rinsed in tap water, dehydrated using ethanol, and mounted in xylene. Stained sections were imaged by the Aperio ScanScope system (Leica Biosystems), and collagen deposition was quantitated using a positive pixel count algorithm using Aperio ImageScope software (Leica Biosystems) by an investigator blinded to treatment groups.
Statistical analyses. All results are presented as means Ϯ SE and were analyzed by one-way ANOVA followed by Fisher's least significant difference multiple-comparison test using OriginPro 2016 (OriginLab, Northampton, MA); P Ͻ 0.05 is considered to be statistically significant.
RESULTS
PLGA particles of sildenafil and rosiglitazone are optimal for deep-lung deposition. Volume-based diameters of sildenafil and rosiglitazone particles, prepared separately for each individual drug, were 4.07 Ϯ 0.85 and 4.32 Ϯ 0.86 m, respectively ( Table 1 ). The size of an inhalable particulate drug formulation dictates its deposition patterns within the respiratory tract (29) . Deposition of drugs in the peripheral lung enhances the penetration and retention of the inhaled formulations and thus produces maximum therapeutic benefits. Both sildenafil and rosiglitazone particles show an optimum physical diameter (~5 m) that is optimal for deposition in the alveolar region upon inhalation (4, 22, 29) . The drug loading efficiencies of these formulations were also high (76.86 Ϯ 4.50% for sildenafil and 84.19 Ϯ 5.70% for rosiglitazone). Increased drug loading helps reduce the total amount of formulations to be delivered for a given dose and thus minimizes excipientinduced complications in the lungs. These formulations continued to release the drugs for over 24 h.
Combination of sildenafil and rosiglitazone particles elicited maximal reduction in mPAP but minimal reduction in mSAP. The mPAP of control animals (sham animals) was the same as the physiological value (14.2 Ϯ 1.9 mmHg, Fig. 2A ). In vehicle-treated PAH animals, the mPAP was 3.7-fold of the physiological mPAP (52.3 Ϯ 5.1 mmHg), suggesting that the ani-mals had a severe form of PAH. However, PAH rats that received either sildenafil or rosiglitazone, given once a day for 21 days via the oral or IT route, showed a 34.8 -47.6% reduction in mPAP compared with PAH rats treated with saline ( Fig. 2A) . Once-a-day treatment with the combination of plain sildenafil plus rosiglitazone, given IT, showed a 43% reduction in mPAP, and once-every-48-h treatment with the combination of particles of sildenafil and rosiglitazone produced a 35.4% reduction in mPAP compared with saline-treated rats. The IT combination of plain drugs, although given twice as frequently as the particle combination via the same route, showed slightly more reduction in mPAP than the IT particle combination did, but the difference was not statistically significant. The extent of reduction in mPAP induced by oral plain drug combination was not statistically significant compared with that in salinetreated PAH rats. The mSAPs in various treatment groups were between 106.6 Ϯ 10.1 and 134.5 Ϯ 13.6 mmHg, indicating Values are means Ϯ SE. PLGA, poly(lactic-co-glycolic acid). that none of the treatments caused drops in systemic blood pressure, a well-known side effect of PAH medications (Fig.  2B ). Although the mSAP in PAH rats (123.26 Ϯ 17.1 mmHg) was slightly greater than that in healthy rats (119.48 Ϯ 19.9 mmHg), there was no statistically significant difference between control and test animals, and thus PAH caused no increase in mSAP.
Combination of sildenafil and rosiglitazone particles improved cardiac function. Representative P-V loop diagrams from each of the 9 treatment groups, obtained from 20 left ventricular P-V loops of the animals (Fig. 3A) , suggest that the stroke volume (the horizontal length of the loop) of the healthy animals was substantially larger than that of the saline-treated PAH rats. Saline-treated PAH rats had the smallest stroke volume, as evidenced by the narrowest horizontal width of the loop. Treatment of PAH rats for 21 days with a single or combination therapy with sildenafil and/or rosiglitazone, either in plain form or in particulate formulation, appears to improve the stroke volume of PAH rats.
To assess the effect of the treatments in ameliorating functional deterioration of the heart, we measured CI, the body weight-normalized function of cardiac output in PAH rats (36, 57) . A 60.7% reduction in mean CI in saline-treated PAH rats compared with sham animals suggests a major deterioration of cardiac output due to the development of PAH (Fig. 3B ). The effect of oral sildenafil, oral rosiglitazone, and IT rosiglitazone on mean CI was rather modest, but IT sildenafil improved the CI by 22.3% compared with saline-treated PAH rats. IT plain drug combination caused a 31% improvement in mean CI; the variability was rather high with a relative standard error (RSE) of~28.4%. Oral combination therapy reduced the mean CI by 3.1%. However, IT sildenafil plus rosiglitazone particles, administered every 48 h, produced a 17.7% improvement in mean CI compared with saline-treated groups, and the variation in this treatment group was rather small (RSE,~7%).
To evaluate the effects of various treatments in reducing pulmonary vascular resistance, a major indicator of PAHassociated vascular remodeling, we assessed TPVR for different groups (3, 31) . Saline-treated PAH rats showed a 6.1-fold increase in TPVR compared with sham animals, an indication of abnormally high mPAPs observed in saline-treated PAH rats (Fig. 3C) . Despite a major reduction in mean TPVR in PAH rats treated with oral sildenafil and oral and IT rosiglitazone, within-group variability was very high (RSE Ͼ 29%). The TPVRs in IT sildenafil-and IT plain drug combination-treated PAH rats were 58% lower than that in saline-treated PAH rats. However, unlike other treatment groups, within-group variation was small. Rats treated with the combination of the particles of the two drugs showed a 47.1% reduction in TPVR with low intersubject variability (RSE, 19.4%) compared with the saline-treated PAH rats.
Combination of sildenafil and rosiglitazone particles reduced RVH in PAH rats. We evaluated the effects of different treatments in reducing the extent of RVH, the major contributor to the death of 80% of patients with PAH (38) . An increase in RV/LVϩS indicates right heart enlargement (1) . Sugen 5416-hypoxia caused significant RVH in vehicle-treated PAH rats as evidenced by a twofold increase in RV/LVϩS compared with that of the healthy rats (Fig. 4) . Once-a-day treatment with IT rosiglitazone showed a 10.5% reduction in RV/LVϩS. Oral plain sildenafil, given either as a single drug or in combination with oral plain rosiglitazone, caused no statistically significant changes in RV/LVϩS compared with that of the vehicle-treated controls. Compared with the vehicletreated PAH rats, RV/LVϩS in the IT sildenafil-treated group declined by 5.3%. IT combination of plain sildenafil and rosiglitazone showed a statistically significant reduction (16.4%) in RV/LVϩS. However, combination therapy with sildenafil plus rosiglitazone particles showed the greatest reduction (21.8%) in RV/LVϩS, which was statistically significant compared with that of the vehicle-treated PAH rats.
IT combination of sildenafil and rosiglitazone improved pulmonary arterial remodeling. In PAH, muscularization and remodeling of both extracellular matrices and pulmonary arteries cause narrowing of the pulmonary arteries and arterioles (25) . Thus, we immunostained vWF and ␣-SMA in the lungs and used them as markers for endothelial and smooth muscle cell activation, respectively (Fig. 5A) . The vascular walls of the pulmonary arteries of the saline-treated PAH rats were thicker than those of sham animals (Fig. 5A) , pointing to the arterial remodeling due to PAH. When treated with IT plain sildenafil, IT plain rosiglitazone, IT combination of plain drugs, and IT combination of particles, arterial thickening declined, pointing to the preventive effects of the formulations on endothelial and smooth muscle proliferation (Fig. 5A) .
We calculated mean arterial thickening (MWT) to quantify the degree of arterial thickening in different treatment groups (Fig. 5B) . The MWT in vehicle-treated PAH lungs was~2-fold greater than that in sham animals. Except in the IT particle combination group, MWTs in all treatment groups were smaller than those in the vehicle-treated group, and the differences between the groups were statistically significant. Compared with the vehicle-treated group, the reduction in MWTs in the once-every-48-h treatment (21.3%) group was no different from IT once-a-day treatment with plain drug combination (24.45%). However, statistically, there was no difference in the MWTs of various treatment groups.
We also quantified the number of occluded vessels present in each large microscopic field of the stained lung sections of different treatment groups (Fig. 5C ). The number of occluded vessels in vehicle-treated PAH rats was 4.1 times greater than that in sham rats. Compared with the vehicle-treated group, drug treatment caused a significant decrease in the number of occluded vessels across all the treatment groups. Similar to the MWT data, there were no statistically significant differences among the seven groups that received various treatments with drugs or formulations.
Sildenafil and/or rosiglitazone reduced arterial collagen deposition. A major pathophysiological feature of PAH is the deposition of extracellular matrix proteins, such as collagen fibers, in the pulmonary arteries (52, 68) . Thus, we assessed the effect of the formulations on collagen deposition. In PAH rats, the deposition of collagen was much higher than that in sham animals (Fig. 6A ). However, collagen deposition declined in all drug-treated groups, except oral sildenafil, although the extent of collagen deposition in various treatment groups was not statistically different (Fig. 6B ). However, in saline-treated PAH animals, collagen deposition was 38.6% higher than in healthy animals, suggesting the presence of progressive PAH. However, IT plain sildenafil treatment caused an~24.0% reduction, and the combination of particles caused a 10.1% 
DISCUSSION
Currently, sildenafil, although used extensively as a vasodilator for PAH management, cannot adequately improve pulmonary hemodynamics and slow PAH progression (51) . First, dose-related adverse events limit the use of sildenafil in pediatric patients with PAH (51, 62) . Systemic adverse events often preclude escalation of sildenafil dose in patients with PAH who become unresponsive to this drug. As such, these patients are left with the options of dual-or triple-combination therapies (12, 13) . Recently, we have shown that an inhalable low-dose sustained release formulation of sildenafil elicits hemodynamic relief in PAH rats for an extended period,~6 h (48) . Rosiglitazone is known to be effective in preventing right heart remodeling, the major cause of PAH-related mortality. While vasodilator-based combination therapy is the mainstay for PAH management (12), here we evaluated the long-term effects of an inhaled combination therapy, given as a sustainedrelease inhalable formulation that can accomplish major treatment goals: to provide hemodynamic relief, to improve arterial remodeling, and to reduce RVH. More to this point, patients with PAH often fail to comply with or adhere to a given treatment regimen because of the requirement of multiple dosing a day. Indeed, too many doses a day can seriously erode patients' freedom and lead to noncompliance. As shown above and discussed below, the PLGA formulations of sildenafil and rosiglitazone that we have developed can potentially be administered every other day instead of every day or multiple times a day because the formulations, given every 48 h, are as efficacious in ameliorating various PAH pathologies as the plain drugs given every day.
We used a Sugen-hypoxia rat model of PAH because it most closely resembles human PAH. This model exhibits high mPAP, manifests vascular changes similar to those of human PAH, and protects animals from non-PAH-associated mortality (6, 53) . The highest daily dose of sildenafil for adult patients with PAH is 60 mg, equivalent to 5.4 mg·kg Ϫ1 ·day Ϫ1 in rats as per US Food and Drug Administration guidance on interspecies dose conversion (60, 61) . In this study, the dose for sildenafil particles was 0.25 mg·kg Ϫ1 ·day Ϫ1 , which is Ͻ1/20th of the approved dose in humans. Similarly, the rat-equivalent dose for rosiglitazone (4 mg/day) in patients with diabetes is 0.36 mg·kg Ϫ1 ·day Ϫ1 , and the dose of rosiglitazone particles was 0.15 mg·kg Ϫ1 ·day Ϫ1 , one-half of the regular human dose for diabetes (59) . Thus, the novel aspect of this study was the evaluation of the long-term efficacy of a low-dose and pulmonary-specific combination therapy comprising a vasodilator and an inhibitor of vascular remodeling in PAH.
The physicochemical properties of both sildenafil and rosiglitazone particles are identical and suggest that these particles are most likely to be distributed in the alveolar region of the lungs upon inhalation (4, 22, 29) . High drug loading efficiency, observed in the case of both sildenafil and rosiglitazone particles, is a major advantage because it eases drug administration with the microsprayer and reduces IT administration-associated trauma in rats (8) . Systemic and pulmonary hemodynamics of the Sugen 5416-hypoxia rats that did not receive any of the drugs suggest development of moderate to severe forms of PAH as previously reported (42, 55) . Once-aday administration of a single drug, either given orally or IT for 21 days, slowed the progression of PAH, as evidenced by the significantly reduced mPAPs in treatment groups compared with the vehicle-treated control group. Lack of effects in the oral plain drug combination group can be attributed to the poor absorption from the gastrointestinal tract. Combination particles, although given every 48 h, were as effective as the plain drug combination given once a day IT because PLGA particles released the drugs slowly but continuously over a longer period on the highly absorptive alveolar surface (20, 44, 46, 48) . The systemic arterial pressure remained unaltered perhaps because the doses of the drugs were too small to produce a measurable systemic effect. The mSAPs in healthy sham rats were very close to those in PAH rats, suggesting that PAH development had no effect on the systemic pressure. Together, hemodynamic data suggest that particles of sildenafil and rosiglitazone can effectively restrain disease progression with less frequent dosing.
We observed a deterioration of cardiac function in the PAH rats that received no drugs. Representative P-V loops and CI from different treatment groups suggest that Sugen-hypoxia produced severe PAH that significantly limited cardiac output as previously documented (1, 2, 37, 42) . IT plain sildenafil or IT plain drug combination appeared to restore the CI slightly although there was a higher interanimal variability. Combination particles showed a moderate improvement in CI with low intersubject variability. High pulmonary vascular resistance (Ͼ3 mmHg·l Ϫ1 ·min Ϫ1 ) is an integral part of the hemodynamic definition of PAH that distinguishes PAH from other forms of pulmonary hypertension (23) . We calculated TPVR, as an indirect measure for pulmonary vascular resistance, to assess disease progression as well as the effect of different treatments (5) . Similar to CI, a significant increase in TPVR in the vehicle-treated group suggests worsening of PAH. IT sildenafil, IT plain drug combination, and IT combination particles reduced TPVR to half of that observed in saline-treated PAH rats. Reduction in TPVR produced by combination particles can be attributed to the sustained pulmonary vasodilation and inhibition of vascular remodeling by sildenafil and rosiglitazone at the local pulmonary vasculature (7, 21, 28, 46, 48) . Altogether, our study indicates a functional deterioration of the cardiac parameters in Sugen-hypoxia-induced PAH and that sildenafil plus rosiglitazone improves the cardiac functional capacity in diseased rats.
RV/LVϩS is used to evaluate PAH-associated right heart remodeling in preclinical models (1, 20, 42) . All but the oral plain drug combination treatments caused a statistically significant reduction in PAH-induced RVH, as reflected by the elevated RV/LVϩS. Although the effects within the drug-treated groups were not statistically significant, the greatest reduction in RV/LVϩS being observed in the IT combination particle group suggests that prolonged and pulmonary-preferential effects of the drugs are more effective in reducing RVH.
In PAH, rapid proliferation of the smooth muscle cells of the medial layer along with endothelial dysfunction causes narrowing of the small pulmonary arterioles (25) . Furthermore, progression of PAH involves proliferation of both endothelial and smooth muscle cells in the pulmonary arteries (26, 35, 45) . Qualitative micrographs and quantitative morphometry of the lung tissues indicate that single drugs or plain drug combinations were effective in preventing arterial thickening; combination particles, administered at a longer interval, inhibited arterial thickening to the same extent although plain drug versus particle combination-induced effects were not signifi- cantly different. The number of muscularized vessels in drugtreated groups versus saline-treated rats confirmed that particles, given at the same dose but at a longer dosing interval (24 vs. 48 h), produced similar improvements in arterial muscularization. Thus, echoing the observed hemodynamic effects, morphometric analyses suggest that the PLGA formulations of these drugs can be given at a longer interval to produce similar effects in preventing arterial muscularization and thickening. Collagen accumulation is a key contributor to the pulmonary arterial stiffening and remodeling in PAH (10, 43, 58) . In the present study, a moderate increase in the mean collagen content in the vehicle-treated group compared with that in the healthy rats suggests that hyperactive collagen synthesis was implicated in disease progression. Hemodynamic improvement caused by the treatments should reduce collagen deposition, but we found no statistically significant differences between treatment and control groups. Lower collagen content in IT sildenafil and combination particle groups compared with the untreated controls indicates a trend toward slowing of PAH progression. A long-term study for 12 wk would perhaps help determine the effect of this drug combination on collagen deposition.
However, the efficacy data may not be on par with the safety of the formulation, which should be assessed after chronic administration of the formulations to both control and PAH rats. Rosiglitazone-induced changes, for example, in the liver should be carefully evaluated, although the dose of this drug used here is much smaller than the US Food and Drug Administration-approved dose. We previously evaluated the safety of the inhalable sildenafil particles after a single dose in healthy rats (46, 48) , but a long-term safety study of the proposed combinations has not yet been conducted. More importantly, a survival study using PAH animals would provide further credence to the assumption that the combination of sildenafil and rosiglitazone improves both cardiac function and arterial remodeling in PAH animals.
In conclusion, in this study, we showed that a novel combination therapy comprising PLGA particles of two distinct drugs, sildenafil and rosiglitazone, produced similar improvement in PAH pathology at a longer dosing interval compared with the combination of two plain drugs. The proposed therapy selectively reduced mPAP, improved cardiac function by increasing cardiac output and decreasing total pulmonary resistance, compensated for ventricular insufficiency by reducing RVH, and slowed disease progression by reducing collagen deposition and muscularization of the pulmonary arteries. Thus, this combination of inhaled long-acting particles of sildenafil plus rosiglitazone can potentially be translated into a clinically viable drug delivery system.
